At PromiseCare Medical Group in Hemet, California, Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a specialized treatment that offers new hope for patients with limited peritoneal disease. This innovative approach combines heated chemotherapy with surgery to target abdominal cancers, often resulting in improved survival rates and reduced cancer recurrence.
By administering heated chemotherapy directly into the abdominal cavity, HIPEC enhances drug absorption and attacks residual cancer cells more effectively.
As a treatment option, HIPEC is tailored to each patient’s specific needs, considering the type and extent of their cancer. At PromiseCare Medical Group, medical professionals work closely with patients to determine the best course of treatment, providing personalized care and support throughout the process.
Patients who undergo HIPEC can experience enhanced quality of life and improved outcomes, making this complex yet potentially life-changing treatment an essential consideration for those with abdominal cancers.
The medical team at PromiseCare Medical Group has extensive experience with HIPEC, having successfully treated numerous patients with this innovative approach.
By leveraging their expertise and staying up-to-date with the latest research and advancements, they provide the highest level of care for patients with peritoneal disease.
For those seeking a comprehensive and compassionate treatment plan, PromiseCare Medical Group is a trusted partner in their journey towards recovery and wellness.
Overview
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a groundbreaking approach to cancer treatment, particularly for patients with abdominal cancers. This innovative procedure combines cytoreductive surgery with heated chemotherapy delivered directly into the abdominal cavity, targeting residual cancer cells.
The heated chemotherapy, typically administered at temperatures between 41-43°C (approximately 106-109°F), enhances drug absorption and effectiveness against tumors.
HIPEC specifically targets cancer cells in the peritoneal cavity, providing a localized treatment approach. It’s primarily used for treating cancers that spread to the peritoneum, such as ovarian, colorectal, and gastric cancers.
During the 90-minute to 2-hour procedure, heated chemotherapy is circulated throughout the abdominal cavity to guarantee thorough coverage. By delivering chemotherapy directly to the affected area, HIPEC considerably improves local drug concentration and reduces systemic side effects.
While it isn’t a cure for cancer, HIPEC offers a treatment option for patients seeking effective management of their condition.
Types
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a treatment approach for various types of abdominal cancers. It has proven effective against cancers that have spread to the peritoneum, including ovarian, colorectal, gastric, appendix, and adrenal cancers. HIPEC involves circulating heated chemotherapy drugs directly into the peritoneal cavity to target cancerous tumors, increasing the chances of eradicating the disease.
Patients with limited peritoneal disease may undergo HIPEC. The treatment typically involves cytoreductive surgery to remove visible tumors, followed by HIPEC to target microscopic cancer cells. This two-step approach has shown improved survival rates and long-term outcomes compared to traditional chemotherapy methods.
Both adult and pediatric patients can benefit from HIPEC, which offers hope for individuals with advanced abdominal cancers. However, candidacy is carefully assessed based on overall health, extent of disease spread, and specific cancer type.
HIPEC represents a significant advancement in cancer treatment, providing a promising option for those battling abdominal cancers.
Why it’s done
HIPEC is an essential treatment option for abdominal cancers that have spread to the peritoneum, as traditional chemotherapy often fails in such cases. Cancer cells can hide and grow when they reach the abdominal cavity’s lining. HIPEC is designed to track them down and eliminate them.
After surgery to remove the visible tumor, residual cancer cells may still be present in the abdominal cavity. HIPEC aims to eradicate these leftover cells by bathing the cavity in heated chemotherapy, reducing the risk of cancer recurrence.
The heat increases the chemotherapy’s effectiveness, allowing higher doses to be used without causing systemic side effects. This targeted approach delivers the treatment directly to the cancer site, maximizing its impact while minimizing harm to healthy tissues.
HIPEC provides a treatment option for abdominal cancer, offering a chance to regain control over one’s health.
Who it’s for
Several types of abdominal cancers can benefit from HIPEC surgery, including ovarian, colorectal, appendiceal, gastric cancers, and peritoneal carcinomatosis. Patients with one of these cancers may be candidates for HIPEC if they’ve limited peritoneal disease and have undergone successful cytoreductive surgery to remove visible tumors.
To be considered for HIPEC, patients typically need to be in good physical shape and meet specific surgical operability criteria. Those with severe comorbidities, such as lung or liver disease, may not qualify. A thorough evaluation by an oncologist, considering the patient’s condition, medical history, and overall health, is essential to determine candidacy.
The benefits of HIPEC may be more significant for younger patients, particularly those under 60, especially when combined with cytoreductive surgery.
Patients must discuss their options with their oncologist to determine if HIPEC is a safe and effective treatment for their abdominal cancer. By working together, patients can make an informed decision about their care.
Risks
Understanding the Risks of HIPEC for Abdominal Cancer Treatment
HIPEC is a complex procedure with a morbidity rate of approximately 33%, which can lead to complications like prolonged intestinal atony and delayed wound healing. The mortality rate associated with HIPEC procedures is around 2.8%.
It’s essential to be aware of these risks when considering HIPEC for treating abdominal cancer.
Common side effects of HIPEC include pain, nausea, diarrhea, and fatigue, which may require careful management during recovery. The overall health condition, age, extent of peritoneal carcinoma, and duration of the surgery are specific risk factors that can increase the likelihood of complications.
Close monitoring during and after the HIPEC procedure is crucial to detect and address potential complications promptly. Medical teams take proactive steps to minimize risks and ensure a smooth recovery.
Understanding the risks and taking proactive steps allows patients to make informed decisions about undergoing HIPEC for abdominal cancer treatment.
Individual risk profiles vary, and discussing specific risk factors with a medical professional is critical. Patients can better navigate the treatment process by being aware of the potential complications and taking proactive steps.
How you prepare
Preparing for HIPEC surgery for abdominal cancer treatment involves a thorough preoperative evaluation to assess overall health and determine eligibility for the procedure. This evaluation includes a detailed medical history, tumor assessment, and cardiopulmonary analysis.
Imaging studies are also conducted to assess the extent of the cancer, ensuring ideal surgical planning. Discussing current medications and any allergies, particularly chemotherapy agents, with the healthcare team is essential to avoid complications.
Nutritional status is evaluated, and a specific diet or nutritional supplementation may be recommended in preparation for surgery. Instructions about fasting prior to the procedure, including when to stop eating and drinking, are provided to guarantee safety during anesthesia.
Sharing medical history, including any previous surgeries, medical conditions, and medications, is crucial. This thorough evaluation helps determine the best course of treatment and ensures a safe and successful procedure.
Active participation in the preoperative evaluation prepares patients for surgery and allows them to focus on recovery.
What you can expect
The HIPEC procedure is a highly specialized and complex operation that requires careful planning and execution. The surgery involves removing any visible tumors from the abdominal cavity.
Once the surgery is complete, heated chemotherapy drugs are delivered directly into the abdominal cavity to target any remaining cancer cells. This process, known as hyperthermic intraperitoneal chemotherapy (HIPEC), lasts approximately 90 minutes to 2 hours, during which the patient may be repositioned to guarantee thorough distribution of the chemotherapy solution.
As patients recover from the procedure, they can expect to experience some side effects, including:
- Nausea and vomiting
- Fatigue and weakness
- Abdominal discomfort or pain
- Loss of appetite
The recovery time depends on the individual’s health and the extent of the surgery, but patients can expect to spend several days to two weeks in the hospital.
It’s essential to maintain open communication with healthcare providers during this time and report any concerning symptoms such as fever, persistent nausea, or worsening pain. With proper care and support, patients can recover from the procedure.
Results
Chances of survival and quality of life after a HIPEC procedure are significantly influenced by the effectiveness of the treatment in eliminating cancer cells from the abdominal cavity. Research has shown that HIPEC improves overall survival rates for patients with peritoneal carcinomatosis, particularly in appendiceal, colorectal, and ovarian cancers.
Studies report up to a 40% increase in overall survival compared to traditional treatments. Combining HIPEC with cytoreductive surgery results in a median overall survival of approximately 53 months.
HIPEC also reduces cancer recurrence rates, which range from 30% to 50% for HIPEC patients, compared to higher rates for those receiving systemic chemotherapy alone.
However, there are potential risks, including a morbidity rate of around 33% and a mortality rate of approximately 2.8%. These risks highlight the importance of careful patient selection and monitoring.
Understanding the results of HIPEC and discussing individual situations with a healthcare provider allows patients to make informed decisions about whether this treatment is suitable. With HIPEC, patients may achieve improved survival rates and a better quality of life.